These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9436478)

  • 1. [Treatment of familial combined hyperlipidemia].
    Bruckert E
    Ann Endocrinol (Paris); 1997; 58(4):297-301. PubMed ID: 9436478
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
    Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
    Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Pehlivanidis AN; Kontopoulos AG
    J Cardiovasc Risk; 2002 Feb; 9(1):33-9. PubMed ID: 11984215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin-fibrate combinations in patients with combined hyperlipedemia.
    Athyros VG; Papageorgiou AA; Kontopoulos AG
    Atherosclerosis; 2001 Mar; 155(1):263-4. PubMed ID: 11293392
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
    Schonfeld G
    Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Mikhailidis DP; Jagroon IA
    Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug interactions with fibric acids.
    Lozada A; Dujovne CA
    Pharmacol Ther; 1994 Aug; 63(2):163-76. PubMed ID: 7809177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of fibrate therapy for homocysteine.
    Goffin E; Jamar F; Desager JP; Devuyst O
    Lancet; 1999 Oct; 354(9185):1209. PubMed ID: 10513738
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug treatment of combined hyperlipidemia.
    Wierzbicki AS; Mikhailidis DP; Wray R
    Am J Cardiovasc Drugs; 2001; 1(5):327-36. PubMed ID: 14728015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid profiles on fibric-acid derivatives.
    Capps NE
    Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
    [No Abstract]   [Full Text] [Related]  

  • 11. [The action of a fibric acid derivative on lipid metabolism].
    Filip M; Păduraru I; Nechifor M; Dănilă GH; Popovici I; Filip FM; Poşircă F
    Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):573-6. PubMed ID: 2636755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal lipid profiles on fibrate derivatives.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat.
    Charmoillaux M; Goudonnet H; Mercenne F; Mounié J; Truchot RC
    Cell Mol Biol; 1991; 37(8):765-71. PubMed ID: 1807786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciprofibrate and lipid profile.
    Chandler HA; Batchelor AJ
    Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract]   [Full Text] [Related]  

  • 15. [The treatment of chronic ischemic heart disease: the potentials for hypolipidemic correction using current drugs].
    Tashchuk VK; Makoviĭchuk IO; Bilets'kyĭ SV; Hrechko SI; Polishchuk OIu; Turubarova NA
    Lik Sprava; 1998; (5):101-3. PubMed ID: 9793321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term treatment of hyperlipoproteinemia with etofibrate].
    Bartz VT; Gatz J; Slotty C; Schröter C; Töle R; Wand P
    Fortschr Med; 1993 Sep; 111(25):398-400. PubMed ID: 8406286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experimental research on the action of a derivative from a p-chloropenoxyisobutyric acid series on lipid parameters].
    Filip M; Hriscu A; Păduraru I; Rusu M
    Rev Med Chir Soc Med Nat Iasi; 1986; 90(1):156-60. PubMed ID: 3764166
    [No Abstract]   [Full Text] [Related]  

  • 18. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO; Hjelm CJ; Canepo-Anson R
    Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cytolytic hepatic damage caused by ciprofibrate].
    Perault MC; Fievre JL; Dejean C; Martin A; Vandel B
    Gastroenterol Clin Biol; 1992; 16(6-7):609. PubMed ID: 1526424
    [No Abstract]   [Full Text] [Related]  

  • 20. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
    Harvengt C
    Acta Clin Belg; 1991; 46(2):117-9. PubMed ID: 1649529
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.